Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
13.51 BRL | -17.42% | -15.35% | +133.74% |
Apr. 18 | Biocon Signs Licensing and Supply Pact with Biomm to Commercialize Generic Ozempic in Brazil | MT |
Apr. 17 | Biocon Limited Signs an Exclusive Licensing and Supply Agreement with Biomm S.A | CI |
Sales 2022 | 105M 20.4M | Sales 2023 | 118M 22.98M | Capitalization | 470M 91.33M |
---|---|---|---|---|---|
Net income 2022 | -92M -17.88M | Net income 2023 | -81M -15.75M | EV / Sales 2022 | 5.9 x |
Net Debt 2022 | 67.72M 13.17M | Net Debt 2023 | 125M 24.28M | EV / Sales 2023 | 5.03 x |
P/E ratio 2022 |
-5.37
x | P/E ratio 2023 |
-5.93
x | Employees | 130 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 47.6% |
1 day | -17.42% | ||
1 week | -15.35% | ||
Current month | -33.09% | ||
1 month | -15.56% | ||
3 months | +34.16% | ||
6 months | +119.67% | ||
Current year | +133.74% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | - | - | |
Director of Finance/CFO | - | 19-04-15 | |
Luciano Vilela
CTO | Chief Tech/Sci/R&D Officer | - | 14-02-19 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 74 | 14-01-31 | |
Director/Board Member | 84 | 15-10-12 | |
Director/Board Member | 81 | 13-12-15 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-23 | 13.51 | -6.51% | 50,600 |
24-05-22 | 14.45 | -4.24% | 142,900 |
24-05-21 | 15.09 | -3.39% | 239,600 |
24-05-20 | 15.62 | -0.51% | 90,900 |
24-05-17 | 15.7 | -1.63% | 28,700 |
Delayed Quote Sao Paulo, May 23, 2024 at 04:07 pm EDT
More quotes1st Jan change | Capi. | |
---|---|---|
+133.74% | 250M | |
+10.79% | 116B | |
+11.65% | 106B | |
-6.20% | 23.89B | |
-2.33% | 21.58B | |
-6.03% | 18.96B | |
-13.41% | 16.33B | |
-40.50% | 16.96B | |
+6.64% | 14.14B | |
+31.84% | 12.02B |
- Stock Market
- Equities
- BIOM3 Stock